心力衰竭患者转为沙库巴曲/缬沙坦后肾功能变化及预后
本研究基于PARADIGM-HF和PARAGON-HF两项试验,评估心力衰竭患者初始暴露于沙库巴曲/缬沙坦后出现中度eGFR下降(>15%)与后续心血管结局及治疗获益的关联。结果显示,在PARADIGM-HF中11%、PARAGON-HF中10%的患者发生eGFR下降,但该下降与临床结局无一致关联,且沙库巴曲/缬沙坦相比RASi的治疗获益不受eGFR下降影响。
要点
- 沙库巴曲/缬沙坦初始治疗期间eGFR下降>15%的发生率在两项试验中分别为11%和10%。
- eGFR下降与后续临床结局无一致关联,且不改变沙库巴曲/缬沙坦的长期治疗获益。
- 早期eGFR变化不应阻止沙库巴曲/缬沙坦的继续使用或剂量上调。
核心结论
- 从RASi转为沙库巴曲/缬沙坦时出现中度eGFR下降与不良结局无一致关联,且沙库巴曲/缬沙坦的长期获益在广泛的eGFR下降范围内得以保留。
研究设计与样本
- 研究基于PARADIGM-HF和PARAGON-HF两项随机对照试验,患者经序贯导入期分别滴定至依那普利10 mg每日两次后转为沙库巴曲/缬沙坦97 mg/103 mg每日两次(PARADIGM-HF),或缬沙坦80 mg每日两次后转为沙库巴曲/缬沙坦49 mg/51 mg每日两次(PARAGON-HF)。
主要发现
- 在随机化参与者中,PARADIGM-HF有11%、PARAGON-HF有10%的患者在沙库巴曲/缬沙坦导入期出现eGFR下降>15%。
- 无论随机化后继续沙库巴曲/缬沙坦还是换用RASi,eGFR从最低点至随机化后第16周均部分恢复。
- 初始eGFR下降与两项试验的临床结局均无一致关联。
- 沙库巴曲/缬沙坦 vs RASi对主要结局的治疗获益在有无导入期eGFR下降的患者中相似:PARADIGM-HF中eGFR下降者HR 0.69(95%CI 0.53-0.90),无下降者HR 0.80(95%CI 0.73-0.88),Pinteraction=0.32;PARAGON-HF中eGFR下降者RR 0.84(95%CI 0.52-1.36),无下降者RR 0.87(95%CI 0.75-1.02),Pinteraction=0.92。
- 沙库巴曲/缬沙坦的治疗效应在广泛的eGFR下降范围内保持一致。
关键数值与推荐
- eGFR下降定义为>15%。
- PARADIGM-HF中沙库巴曲/缬沙坦目标剂量为97 mg/103 mg每日两次,PARAGON-HF中为49 mg/51 mg每日两次。
临床怎么用
- 对于心力衰竭患者,从RASi转为沙库巴曲/缬沙坦时出现的早期eGFR变化不应妨碍继续使用沙库巴曲/缬沙坦或阻止剂量上调。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some patients with heart failure may experience transient changes in kidney function upon transition to sacubitril/valsartan. Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan continuation is unknown. OBJECTIVES: This investigation aimed to evaluate the association between the occurrence of moderate estimated glomerular filtration rate (eGFR) decline (>15%) after initial exposure to sacubitril/valsartan and subsequent cardiovascular outcomes and its treatment benefits in PARADIGM-HF and PARAGON-HF. METHODS: In sequential run-in phases, patients were titrated to enalapril 10 mg twice daily and then sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF) or valsartan 80 mg twice daily and then sacubitril/valsartan 49 mg/51 mg twice daily (in PARAGON-HF). RESULTS: Among randomized participants, 11% in PARADIGM-HF and 10% in PARAGON-HF experienced eGFR decline (>15%) during sacubitril/valsartan run-in. eGFR partially recovered (from nadir to postrandomization week 16) regardless of sacubitril/valsartan continuation or switch to renin-angiotensin system inhibitor (RASi) postrandomization. Initial eGFR decline was not consistently associated with clinical outcomes in either trial. Treatment benefits of sacubitril/valsartan vs RASi on primary outcomes were similar irrespective of run-in eGFR decline in PARADIGM-HF (eGFR decline, HR: 0.69; 95% CI: 0.53-0.90; and no eGFR decline, HR: 0.80; 95% CI: 0.73-0.88; Pinteraction = 0.32) and PARAGON-HF (eGFR decline, rate ratio [RR]: 0.84; 95% CI: 0.52-1.36 and no eGFR decline, RR: 0.87; 95% CI: 0.75-1.02, Pinteraction = 0.92). The treatment effect of sacubitril/valsartan remained consistent across a range of eGFR declines. CONCLUSIONS: Moderate eGFR decline when transitioning from RASi to sacubitril/valsartan is not consistently associated with adverse outcomes, and its long-term benefits are retained in heart failure across a broad range of eGFR declines. Early eGFR changes should not deter continuation of sacubitril/valsartan or stall uptitration. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711; Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitors with Angiotensin-Converting Enzyme Inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255).
引用
- Chatur, Claggett, McCausland, et al. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure. J Am Coll Cardiol. 2023. PMID: 36812948. doi:10.1016/j.jacc.2023.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。